Atlas Trials

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Clinical trial NCT06078982 · UNKNOWN

Trial details

NCT number
NCT06078982
Sponsor
Shanghai East Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Gastric CancerHER2-low-expressing Gastric Cancer
Start date
2023-06-06
Primary completion
2025-08-01
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.